De-labelling severe asthma diagnosis: the challenge of DIPNECH

Caroline Hurabielle; Camille Taillé; Grégoire Prévot; Maud Russier; Alain Didier; Pierre-Olivier Girodet; Magali Colombat; Julien Mazières; Laurent Guilleminault

doi:10.1183/23120541.00485-2021

De-labelling severe asthma diagnosis: the challenge of DIPNECH

ERJ Open Res. 2022 Feb 7;8(1):00485-2021. doi: 10.1183/23120541.00485-2021. eCollection 2022 Jan.

Authors

Affiliations

¹ Dept of Respiratory Medicine, Toulouse University Hospital Centre, Toulouse, France.
² Groupe Hospitalier Universitaire AP-HP Nord-Université de Paris, Hôpital Bichat, Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares; Inserm UMR 1152; CRISALIS F-CRIN, Paris, France.
³ Centre Hospitalier Régional d'Orléans, Orléans, France.
⁴ Center for Pathophysiology of Toulouse Purpan, INSERM U1043, CNRS UMR 5282, Université Toulouse III; CRISALIS F-CRIN, Toulouse, France.
⁵ Université de Bordeaux, Pharmacologie, CIC1401, INSERM U1045, F-33000; CRISALIS F-CRIN, Bordeaux, France.
⁶ Service d'anatomopathologie, CHU de Toulouse, Toulouse France.

Abstract

DIPNECH is a differential diagnosis of severe asthma with no specific biomarkers. Chronic cough and multiple nodules on CT should prompt clinicians to consider this diagnosis. Differentiating DIPNECH from severe asthma remains crucial. https://bit.ly/3mmFbQn.